Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review

Detalhes bibliográficos
Autor(a) principal: Santiago, Alexandre Silva
Data de Publicação: 2021
Outros Autores: Pita, Samuel Silva da Rocha, Guimarães, Elisalva Teixeira
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/16543
Resumo: Leishmaniasis groups some neglected diseases caused by intracellular protozoa Leishmania. Its main clinical forms are the tegumentary (LT) and Visceral (LV). Currently, the therapy against leishmaniasis is based on the use of five drugs: the pentavalent antimonials, amphotericin B and its liposomal formulation, miltefosine, paromomycin and pentamidine. These compounds present limitations that difficult patient’s adherence to treatment, such as high toxicity and the need for prolonged parenteral administration, in addition to the selection of resistant strains. Thus, employing the literature narrative review, we brought a panorama of the current leishmaniasis treatment, its elucidated action mechanisms, attributed toxicity, adverse effects and administration routes. Aiming to point this, the more updated data available in the literature were brought to facilitate access information on therapeutic options, in addition to new therapeutic alternatives and vaccine perspectives against this neglected disease.
id UNIFEI_063bfd14bb6aff1490438a674843f53a
oai_identifier_str oai:ojs.pkp.sfu.ca:article/16543
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative reviewTratamiento de leishmaniasis, limitaciones de la terapéutica actual y la necesidad de nuevas alternativas: Una revisión narrativaTratamento da leishmaniose, limitações da terapêutica atual e a necessidade de novas alternativas: Uma revisão narrativaDoenças NegligenciadasLeishmaniaTratamento FarmacológicoMecanismos moleculares de ação farmacológica.Enfermedades desatendidasLeishmaniaTratamiento FarmacológicoMecanismos moleculares de acción farmacológica.Neglected DiseasesLeishmaniaPharmacological treatmentMolecular mechanisms of pharmacological action.Leishmaniasis groups some neglected diseases caused by intracellular protozoa Leishmania. Its main clinical forms are the tegumentary (LT) and Visceral (LV). Currently, the therapy against leishmaniasis is based on the use of five drugs: the pentavalent antimonials, amphotericin B and its liposomal formulation, miltefosine, paromomycin and pentamidine. These compounds present limitations that difficult patient’s adherence to treatment, such as high toxicity and the need for prolonged parenteral administration, in addition to the selection of resistant strains. Thus, employing the literature narrative review, we brought a panorama of the current leishmaniasis treatment, its elucidated action mechanisms, attributed toxicity, adverse effects and administration routes. Aiming to point this, the more updated data available in the literature were brought to facilitate access information on therapeutic options, in addition to new therapeutic alternatives and vaccine perspectives against this neglected disease.Leishmaniasis es un grupo de enfermedades desatendidas causadas por protozoarios intracelulares del género Leishmania. Sus principales formas clínicas son tegumentario (LT) y visceral (LV). Actualmente, la terapéutica contra leishmaniosis es basada en la utilización de cinco fármacos: los antimoniales pentavalentes, la anfotericina B y su formulación liposomal, la miltefosina, la paromomicina y la pentamidina. Estos compuestos presentan limitaciones que dificultan la adherencia del paciente al tratamiento como: la elevada toxicidad y la necesidad de administración prolongada por vía parenteral, así como una posible selección de cepas resistentes. Así, utilizando la revisión narrativa de literatura, se busca aclarar un panorama del tratamiento actual de la leishmaniasis, sus mecanismos de acción elucidados, su toxicidad, sus efectos adversos y vías de administración. Para tanto, se traen los datos más actuales disponibles en la literatura para facilitar el acceso a las informaciones sobre las opciones terapéuticas, y también de las nuevas alternativas terapéuticas y perspectivas de vacunas contra esta enfermedad desatendida.As leishmanioses são um grupo de doenças negligenciadas causadas por protozoários intracelulares do gênero Leishmania. Suas principais formas clínicas são a tegumentar (LT) e a visceral (LV). Atualmente a terapêutica contra a leishmaniose baseia-se na utilização de cinco fármacos: os antimoniais pentavalentes, a anfotericina B e a sua formulação lipossômica, a miltefosina, a paromomicina e a pentamidina. Estes compostos apresentam limitações que dificultam a adesão do paciente ao tratamento como: a elevada toxicidade e a necessidade de administração prolongada por via parenteral, além da possível seleção de cepas resistentes. Assim, utilizando a revisão narrativa de literatura, buscou-se elucidar um panorama do tratamento atual da leishmaniose, seus mecanismos de ação elucidados, sua toxicidade atribuída, seus efeitos adversos e vias de administração. Para tanto, os dados mais atualizados disponíveis na literatura foram trazidos para facilitar o acesso às informações sobre as opções terapêuticas, além das novas alternativas terapêuticas e perspectivas de vacinas contra esta doença negligenciada.Research, Society and Development2021-06-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1654310.33448/rsd-v10i7.16543Research, Society and Development; Vol. 10 No. 7; e29510716543Research, Society and Development; Vol. 10 Núm. 7; e29510716543Research, Society and Development; v. 10 n. 7; e295107165432525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/16543/14807Copyright (c) 2021 Alexandre Silva Santiago; Samuel Silva da Rocha Pita; Elisalva Teixeira Guimarãeshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSantiago, Alexandre SilvaPita, Samuel Silva da RochaGuimarães, Elisalva Teixeira2021-07-18T21:07:03Zoai:ojs.pkp.sfu.ca:article/16543Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:37:03.950997Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
Tratamiento de leishmaniasis, limitaciones de la terapéutica actual y la necesidad de nuevas alternativas: Una revisión narrativa
Tratamento da leishmaniose, limitações da terapêutica atual e a necessidade de novas alternativas: Uma revisão narrativa
title Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
spellingShingle Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
Santiago, Alexandre Silva
Doenças Negligenciadas
Leishmania
Tratamento Farmacológico
Mecanismos moleculares de ação farmacológica.
Enfermedades desatendidas
Leishmania
Tratamiento Farmacológico
Mecanismos moleculares de acción farmacológica.
Neglected Diseases
Leishmania
Pharmacological treatment
Molecular mechanisms of pharmacological action.
title_short Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
title_full Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
title_fullStr Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
title_full_unstemmed Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
title_sort Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review
author Santiago, Alexandre Silva
author_facet Santiago, Alexandre Silva
Pita, Samuel Silva da Rocha
Guimarães, Elisalva Teixeira
author_role author
author2 Pita, Samuel Silva da Rocha
Guimarães, Elisalva Teixeira
author2_role author
author
dc.contributor.author.fl_str_mv Santiago, Alexandre Silva
Pita, Samuel Silva da Rocha
Guimarães, Elisalva Teixeira
dc.subject.por.fl_str_mv Doenças Negligenciadas
Leishmania
Tratamento Farmacológico
Mecanismos moleculares de ação farmacológica.
Enfermedades desatendidas
Leishmania
Tratamiento Farmacológico
Mecanismos moleculares de acción farmacológica.
Neglected Diseases
Leishmania
Pharmacological treatment
Molecular mechanisms of pharmacological action.
topic Doenças Negligenciadas
Leishmania
Tratamento Farmacológico
Mecanismos moleculares de ação farmacológica.
Enfermedades desatendidas
Leishmania
Tratamiento Farmacológico
Mecanismos moleculares de acción farmacológica.
Neglected Diseases
Leishmania
Pharmacological treatment
Molecular mechanisms of pharmacological action.
description Leishmaniasis groups some neglected diseases caused by intracellular protozoa Leishmania. Its main clinical forms are the tegumentary (LT) and Visceral (LV). Currently, the therapy against leishmaniasis is based on the use of five drugs: the pentavalent antimonials, amphotericin B and its liposomal formulation, miltefosine, paromomycin and pentamidine. These compounds present limitations that difficult patient’s adherence to treatment, such as high toxicity and the need for prolonged parenteral administration, in addition to the selection of resistant strains. Thus, employing the literature narrative review, we brought a panorama of the current leishmaniasis treatment, its elucidated action mechanisms, attributed toxicity, adverse effects and administration routes. Aiming to point this, the more updated data available in the literature were brought to facilitate access information on therapeutic options, in addition to new therapeutic alternatives and vaccine perspectives against this neglected disease.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-22
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/16543
10.33448/rsd-v10i7.16543
url https://rsdjournal.org/index.php/rsd/article/view/16543
identifier_str_mv 10.33448/rsd-v10i7.16543
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/16543/14807
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 7; e29510716543
Research, Society and Development; Vol. 10 Núm. 7; e29510716543
Research, Society and Development; v. 10 n. 7; e29510716543
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052750737965056

Registros relacionados